FDA Approves Modifications to REMS of Platelet Boosters

According to news outlets, the platelet-booster drugs Nplate injection and Promacta tablets are used to treat low blood platelet counts in adults with chronic immune [idiopathic] thrombocytopenia. The US Food and Drug Administration (FDA) has approved modifications to the Risk Evaluation and Mitigation Strategies (REMS) of these drugs, including the removal of certain elements of the REMS. Patients and health care professionals should be aware of the serious risks associated with these drugs, such as bone marrow changes, increased risk of blood clotting and potential worsening of symptoms associated with blood cancer.

As a Riverside personal injury attorney, I feel it is essential to keep a close watch on the news from the FDA in order to aid in making their information more available and, hopefully, help to prevent avoidable injuries. If you’ve suffered adverse health effects through the normal use of a defective drug, speak with a personal injury lawyer experienced in these matters after consulting a healthcare provider in your area.